ethosMEDIA S.A.’s Post

🚨Proof of concept study looking at Terzepitide use in patients with Type 1 Diabetes with BMI >27. 💥Impressive Results:💥 ⬇️ HbA1c by 0.59% at 8 months ⬆️ time in range, with greatest increase in Time in Tight Range (70-140). ⬇️ insulin use by >20 units ⬇️ body weight body weight by >10% at 8 months “Conclusions: Tirzepatide significantly reduced HbA1c and body weight in adults with T1D. A randomized controlled trial is needed to establish efficacy and safety of this drug in T1D.” ‼️Important to note‼️Patients were using CGM during the trial which helps to identify and prevent hypoglycemia events. #type1diabetes #cgm #obesitytreatment https://lnkd.in/ghYPsFDq

Do we need to re-think how we proceed with people who screen positive for #T1D markers? "With the approval of teplizumab by the US Food and Drug Administration in 2022 to delay type 1 diabetes in people at stage 2, there is a need to refine the definition and accuracy of type 1 diabetes staging." "Time to reframe the disease staging system for type 1 diabetes" Read: https://lnkd.in/guci4jBK ##type1diabetes #health #healthcare #science #MedicalResearch #NDAM #HCPs

Could not agree more with the below. In fact, I will take it one step further: there are simply not enough providers trained in obesity medicine to provide this level of care. The answer in the short-term -- especially with growing access to GLP-1s from online sources -- is to utilize technology and AI to provide the best coaching and follow-up possible. I do believe adequate care can be provided -- even if just online -- with the proper guardrails and tech in place. If you are a GLP-1 provider and are not using technology in your practice to drive better outcomes, contact Brian Conyer. "This Teachable Moment case highlights the potential dangers underlying under-supervised prescribing of GLP-1/GIP receptor agonists and affirms the need for strong partnerships between patients and their clinicians during their use. These medications are best used in collaboration with continuity care teams, in context of a patient’s entire health, and in comprehensive risk-benefit assessment throughout the entire duration of treatment." https://lnkd.in/gMqVHkEr

The focus of the pharmaceutical industry is undergoing a shift. Traditionally, the emphasis was on developing treatments for existing diseases. Now, we're witnessing a surge in preventative therapies – medications and interventions aimed at stopping illnesses before they even start. ✅ Why the move towards prevention? - Preventative care: cheaper, healthier patients. - Early intervention: better long-term health. - Patients want to prevent illness, not just treat it. ✅ Examples of preventative approaches: - Vaccines: Prevent infections. - Meds for healthy habits: Lower cholesterol, control blood pressure. - Personalized prevention: Tailor plans based on your genes and health data. ✅ Opportunities for Pharma: - Invest in R&D for preventative treatments (cancer, diabetes, Alzheimer's). - Develop tools for early disease detection. - Partner with healthcare providers for preventative care programs. ✅ Challenges and Considerations: - Preventative care = slow financial gains, need new business models. - Taking preventative meds: educate patients for better adherence. - Affordable preventative care for everyone. The rise of preventative treatments signifies a paradigm shift in the pharmaceutical industry. What are your thoughts? How can the pharmaceutical industry best promote preventative healthcare approaches? Share your insights in the comments! #pharma #prevention #healthcare #innovation #wellness

Another milestone for PolTREG. We are announcing positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes (T1D). “At PolTREG, we believe that PTG-007 has the potential to prevent type-1 diabetes, freeing patients of the life-long burden of having to take frequent insulin injections, and the serious long-term complications of the disease. The results of this study are an important step in that direction,” said Prof Piotr Trzonkowski, PolTREG S.A. Chief Executive Officer.   Here are the main findings, found over a period of up to 12 years during which patients were monitored: ☑ Patients who received PTG-007 continued to secrete insulin, while untreated patients in the control group did not, ☑ Safety measures showed no significant difference in the health status of patients who received Treg therapy compared to the control group, ☑ The duration of disease remission was significantly longer in patients who received PTG-007 compared to the control group.   No other company currently can show similar long-term safety results of Treg therapy in T1D. This is a significant competitive advantage, and paves the way for the launch of a pivotal Phase 2/3 study of PTG-007 – a final step before seeking market authorization.   Read our press release here: https://lnkd.in/dNEyDRK7   #biotech #biotechnology #celltherapy #cellandgenetherapy #autoimmunedisease #diabetes #type1diabetes

🌟 Breakthrough in Diabetes Care 🌟 Scientists at The University of British Columbia have developed an oral insulin drop that offers a pain-free alternative to injections for diabetes patients. This innovation from the Li Lab uses a unique cell-penetrating peptide (CPP) to help insulin be efficiently absorbed under the tongue, simplifying diabetes management. Dr.Shyh-Dar Li and his team have created this solution to improve the quality of life for millions living with diabetes. By making the drug delivery process easier, patients can potentially eliminate the need for frequent and painful insulin injections, improving medication adherence and reducing long-term complications. Key highlights: 🔹 Fast and efficient absorption of insulin without injections 🔹 Utilizes a peptide derived from fish byproducts to aid insulin delivery 🔹 Pre-clinical tests show promising results 🔹 Aims to reduce the risk of cross-contamination and other injection related issues This work is detailed in recent articles in the Journal of Controlled Release. The team is now working to bring this technology to market, hoping to make a significant impact on diabetes care. #DiabetesCare #MedicalInnovation #PharmaceuticalSciences #UBCResearch #HealthTech #DiabetesManagement #OralInsulin #NeedleFree #HealthcareInnovation

🌟 Switching to Semaglutide: A Game Changer for Diabetes Care in China! 🌟 A recent study published in Advances in Therapy reveals that Chinese patients with type 2 diabetes can achieve better health outcomes and lower medical costs by transitioning to once-weekly semaglutide. 🔍 Key Findings: - Increased Life Expectancy: Patients gain an average of 0.02 years. - Enhanced Quality of Life: An additional 0.12 QALYs per patient. - 💰 Cost Savings: Lifetime medical costs decrease by 4,204 CNY per patient! This research underscores the potential of semaglutide to not only improve clinical effectiveness but also provide significant economic benefits, making it a promising option for diabetes management. As healthcare providers and policymakers consider these findings, the integration of semaglutide into standard treatment protocols could revolutionize care for millions living with type 2 diabetes. 👉 Click the link to learn more about this important study! #ClinicalResearches #CostSavings #DiabetesCare #HealthEconomics #HealthcareInnovation #Publications #QualityOfLife #RegulatoryAgencies #Semaglutide #MarketAccess #MarketAccessToday

Dexcom G7 now connects with the Tandem t:slim X2 Insulin Pump for results you can trust, from the most studied CGM. People using the Tandem t:slim X2 Insulin Pump with the Dexcom G7 integration experience; ‣ 2.6 hours more Time in Range per day (†,‡,1) ‣ 11% increase in Time in Range during the day (†,1) ‣ 17% increase in Time in Range at night (†,1) For more info visit: https://lnkd.in/dmQau7Zb #LivingBeyondDiabetes #VitalAireDiabetesZA #Diabetes #T1D #rtCGM #CGM #ContinuousGlucoseMonitor #DiabetesZA #DexcomG7 #G7CGM #Dexcom #SouthAfrica #type1diabetes #diabetesawareness #diabeteslife #diabetesmanagement #diabetescommunity #insulin #diabetic #diabetesdiet #diabetesstrong #diabeteswarrior #diabetescare #diabetesprevention #diabetesadvocate #diabeteseducation #ContinuousGlucoseMonitoring #HbA1cImprovement #TandemInsulinPump *Dexcom CGM systems have been studied in over 50 registered interventional clinical trials (clinicaltrials.gov). Dexcom, Data on File, 2023. † Results obtained with a prior-generation Dexcom CGM System. ‡ Compared to non AID. § Dexcom data also includes studies published later than inclusion criteria of the Peacock review. 1 Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717; 2 Peacock S, et al. Diabetes Ther. 2023;14(5):839-855. MAT-2045

To celebrate #worlddiabetesday I have been looking back at some of the recent work I have supported in relation to CGM access. Enabling access to innovative technologies which support both patient outcomes and potentially the associated costs of diabetes care is imperative! The world is changing for those with both type 1 and type 2 diabetes, let’s keep things moving forward 🙌 - Budget impact analysis of continuous glucose monitoring in individuals with type 2 diabetes on insulin treatment in England https://lnkd.in/dYHyqWHn - Access to CGM devices has been shown to improve outcomes and standardization of CGM access could benefit patient outcomes and associated diabetes spending.  https://lnkd.in/eGBagb8a

The World Health Organization, the International Expert Committee, and the ADA recommend the use of #HbAlc to screen for and diagnose #diabetes. Under defined circumstances, certain groups of children and adults (and all adults aged 35 and older) should be screened for type 2 diabetes. This product is used for the in vitro quantitative determination of the percentage content of glycated hemoglobin (HbA1c) in human whole blood. It is mainly used clinically for the auxiliary diagnosis of diabetes and monitoring of blood sugar levels. Glycated hemoglobin is the product of the combination of hemoglobin in red blood cells and blood sugar in human blood. The combination of blood sugar and hemoglobin to generate glycated hemoglobin is an irreversible reaction and is directly proportional to the blood sugar concentration and remains for about 120 days. The glycated hemoglobin test can usually reflect the patient's blood sugar control in the past 8-12 weeks, and is not affected by factors such as the time of blood draw, whether the patient is fasting, whether the patient is using insulin, etc. Clinical application： Increase: It can reflect the blood sugar control of diabetics in 2-3 months. In addition, Chronic renal failure patients using glucose-containing dialysate for hemodialysis, #thalassemia patients and #leukemia patients also have increased glycated hemoglobin levels. Reduce: Hemolytic and blood loss #anemia, chronic renal failure, chronic persistent hypoglycemia, etc. As an early diagnostic indicator of mild, type Ⅱ and "hidden" diabetes, it can be included in diabetes census and health examination items. It can be adapted to our equipment: Fluorescence Immunoassay Analyzer SZY-H01 / SZY-1100 Website: www.lifeoriginbio.com Email: international@szybio.com #Lifeoriginbiotech #IVD #invitrodiagnosis #biotech #POCT #CLIA #FIA